Global Packaging and Labeling CDMO Market is projected to grow at a CAGR of 9-10% in the coming 5 years by 2027

Growth in the global packaging and labeling market is driven by several factors including increased demand from OEMs to comply with regulatory requirements, cost savings, technical know-how, risk mitigation, increased drug manufacturing, and the rising prevalence of chronic diseases, infectious diseases, and genetic disorders.

(firmenpresse) - Contract Development and Manufacturing Organizations (CDMOs) that specialize in packaging provide a wide range of services, including product development, clinical and commercial API production, medication product manufacturing, primary and secondary packaging, labeling, sterilization, and distribution. They also provide producers specialized packaging solutions for some difficult or niche items.

Demand for Eco-Friendly Packaging and Labeling, as well as Compliance with Regulatory Requirements Factors Driving the Market
The packaging and labeling CDMO business is expanding quickly. CDMOs' packaging and labeling techniques have seen considerable alterations in recent years, reflecting the industry's multidimensional growth. Primarily, sustainability has emerged as a prominent element, with a concentration on ecologically friendly packaging and labeling solutions.

For example,

•Jabil Inc. announced its acquisition of Ecologic Brands, Inc., a notable sustainable packaging manufacturer, in January 2021. This strategic decision significantly expands Jabil's line of sustainable packaging.

Furthermore, severe regulations in industries like as pharmaceuticals and healthcare have boosted the demand for serialization and track-and-trace systems. CDMOs are using sophisticated technologies such as QR codes, RFID, and others to assure regulatory compliance, increase supply chain transparency, and prevent fraud.

Factors Influencing the Global Packaging and Labeling CDMO Market
Global packaging and labeling CDMO market is expected to develop at a healthy rate during the forecast period. Filling and packaging are critical components of the whole contract manufacturing process. The demand for specialized packaging has given rise to a new business known as contract manufacturing. Most businesses now outsource their packaging to organizations that specialize in medicine and device packaging.

The expanding elderly population, severe regulatory requirements of governing bodies, and enhanced packaging technologies are some of the drivers that will drive the global packaging and labeling CDMO market. Furthermore, a lack of in-house packaging skills, knowledge, and financial restrictions



For instance,

?In June 2023, Catalent announced that its OneBio® Suite, an integrated solution encompassing development, manufacturing, and supply, has been expanded to encompass various biologic modalities. This suite provides customers with an all-inclusive service designed to expedite the progression of programs from development to manufacturing. This includes activities such as fill/finish, packaging, and assistance with clinical supply and commercial launch.

North America controls the majority of the global packaging and labeling CDMO market
In the future years, North America is likely to continue to dominate the worldwide market. This is mostly due to the region's growing older population, intensive R&D, and the presence of significant businesses. The Asia-Pacific area, on the other hand, is predicted to have the greatest CAGR throughout the projection period. The Asia-Pacific market is being driven by factors such as technical developments in the packaging industry and increased investments in the healthcare sector.

Competitive Landscape Analysis of the Global Packaging and Labeling CDMO Market
Aphena Pharma Solutions, Eurofins Scientific, Catalent, PCI Pharma, Pfizer CentreOne, Becton, Dickinson & Co, Almac Group, Jabil, Tecomet, and Integer are among the leading competitors in the industry.

Organic and inorganic growth strategies used by firms to get a market foothold
Players operating in this market are adopting both organic and inorganic growth strategies such as collaborations, acquisitions, and new product launches to garner market share.

For instance,

•Almac Pharma Services launched its innovative Ultra-Low Temperature Solutions of commercial packaging, labeling, and distribution services in March 2022 to help with the introduction of Advanced Therapy Medicinal Products (ATMPs) from its European Centre of Excellence. Almac customized services for Just-in-Time labeling, packaging, and serialization at ultra-low temperatures (ranging from -20°C to -80°C) will provide clients with a uniquely tailored experience, ensuring that every aspect of this intricately detailed process is finely adjusted to meet the precise needs of both the client and their valuable product.

The packaging and labeling CDMO market is expanding and expected to gain traction in the coming years as a result of a strong emphasis on developing new drugs and devices, investment in R&D to introduce several advanced products, and aggressive organic and inorganic growth strategies adopted by the players.Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
PresseKontakt / Agentur:
Bereitgestellt von Benutzer: Prathamesh
Datum: 11.09.2023 - 07:32 Uhr
Sprache: Deutsch
News-ID 2062498
Anzahl Zeichen: 5322

Kontakt-Informationen:
Ansprechpartner: Prathamesh Medi Tech
Stadt:

Brussels

Telefon: 0498868079

Kategorie:

Gesundheitswesen - Medizin

Meldungsart: Finanzinformation
Versandart: Veröffentlichung
Freigabedatum: 11.09.2023

Diese Pressemitteilung wurde bisher 636 mal aufgerufen.

Growing Focus on Augmented Reality Spurs 13% CAGR in Global Bionic Contact Lenses Market ...
Bionic contact lenses are an innovative blend of traditional contact lenses and advanced tech, promising to reshape vision correction and AR experiences by overlaying digital information in real time. They offer benefits such as addressing nearsightedness, farsightedness, and astigmatism, while pote

The Bioburden Testing Market Continues Upward Trend with a Projected 12-15% CAGR ...
Bioburden testing, an essential quality control process in pharmaceutical and medical device production, evaluates microbial contamination levels on products, raw materials, and manufacturing settings, including bacteria, fungi, yeasts, and molds. This helps companies assess their sterilization effe

The Cardiac Resuscitation Devices Market is Poised to achieve a CAGR of 6-7% by 2029. ...
Cardiopulmonary resuscitation (CPR), another name for cardiac resuscitation, is an emergency treatment given to people who are experiencing cardiac arrest—a condition in which the heart stops beating efficiently—in an emergency. In order to sustain blood flow and oxygenation to critical organs,

Weitere Mitteilungen von Medi-tech insights

Relaxliegen: Ergonomisch rocks! ...
Was macht ergonomisch geformte Liegen aus? Sie sind so gestaltet, dass sie die natürliche Form und die Bewegungen des menschlichen Körpers optimal unterstützen. Sie bieten eine Reihe von Vorteilen, die die Gesundheit und das Wohlbefinden fördern können, weiß man bei First Class Holz, dem Exper

Für jedes Wehwehchen ist ein Kraut gewachsen ...
Die unsichtbare Kraft der Natur: Erfolgreiche Innovationen in der phytopharmazeutischen Entwicklung für sichere und wirksame Medikamente, von Dr. Rainer Schreiber im Gespräch mit Ridvan Abey, CEO der Helvezia Pharma & Medical Care AG, Schweiz. Die Nachfrage nach sicheren und wirksamen Medik

Invasive Kardiologie: Was ist eine Herzkatheteruntersuchung? ...
SIEGEN. Bei einer Herzkatheteruntersuchung kann das Herz von innen heraus untersucht werden. Alle Herzkammern sowie angrenzende Gefäße sind auf diese Weise zugänglich. Das bietet viele Vorteile, vor allem aber die Option, bei Bedarf gleichzeitig zu behandeln. Die Intervention gilt als risikoarm u

Gehirnstimulation: Transkranielle Pulsstimulation (TPS) zur ambulanten Behandlung der Alzheimer-Krankheit ...
Die Behandlungsmöglichkeiten für Morbus Alzheimer, andere Formen der Demenz, aber auch Parkinson und andere neurodegenerative Erkrankungen haben sich in den letzten Jahren erheblich weiterentwickelt. Während die Forschung nach ursächlichen und symptomatischen Medikamenten gegen Alzheimer und and